(Q37779305)

23 August 2017

1 reference

title

Emerging biomarkers in breast cancer care (English)

1 reference

23 August 2017

0 references

1 reference

Rudolf Napieralski

1

1 reference

23 August 2017

Nils Brünner

series ordinal

2

1 reference

23 August 2017

Karin Mengele

series ordinal

3

1 reference

23 August 2017

Manfred Schmitt

series ordinal

4

1 reference

23 August 2017

publication date

1 August 2010

1 reference

23 August 2017

published in

Biomarkers in Medicine

1 reference

23 August 2017

volume

4

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

505-522

1 reference

Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer

23 August 2017

cites work

1 reference

The cancer biomarker problem

21 January 2018

1 reference

Breast cancer prognostic factors: evaluation guidelines.

21 January 2018

1 reference

Banking of biological fluids for studies of disease-associated protein biomarkers

21 January 2018

1 reference

European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers.

21 January 2018

1 reference

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

21 January 2018

1 reference

Use of archived specimens in evaluation of prognostic and predictive biomarkers

21 January 2018

1 reference

Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy

21 January 2018

1 reference

Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer

21 January 2018

1 reference

Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?

21 January 2018

1 reference

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

21 January 2018

1 reference

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

21 January 2018

1 reference

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

21 January 2018

1 reference

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

21 January 2018

1 reference

The urokinase-type plasminogen activator system in cancer metastasis: a review

21 January 2018

1 reference

Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects

21 January 2018

1 reference

Limited Prognostic Value of c-erbB-2 Compared to uPA and PAI-1 in Primary Breast Carcinoma

21 January 2018

1 reference

Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.

21 January 2018

1 reference

International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy

21 January 2018

1 reference

New data on chemotherapy in the adjuvant setting

21 January 2018

1 reference

Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.

21 January 2018

1 reference

Neoadjuvant therapy for breast cancer

21 January 2018

1 reference

Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting.

21 January 2018

1 reference

DNA topoisomerase I and II as targets for rational design of new anticancer drugs

21 January 2018

1 reference

Structure and mechanism of DNA topoisomerase II

21 January 2018

1 reference

Culprit and victim -- DNA topoisomerase II.

21 January 2018

1 reference

HER2/neu in systemic therapy for women with breast cancer: a systematic review

21 January 2018

1 reference

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:

21 January 2018

1 reference

Aberrations of ERBB2 and TOP2A genes in breast cancer.

21 January 2018

1 reference

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).

21 January 2018

1 reference

Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?

21 January 2018

1 reference

TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis

21 January 2018

1 reference

Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.

21 January 2018

1 reference

HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients

21 January 2018

1 reference

Telling cells how to die: docetaxel therapy in cancer cell lines.

21 January 2018

1 reference

Markers predicting clinical benefit in breast cancer from microtubule-targeting agents

21 January 2018

1 reference

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer

21 January 2018

1 reference

Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial

21 January 2018

1 reference

Molecular basis of antifolate resistance

21 January 2018

1 reference

Participation of DNA repair in the response to 5-fluorouracil

21 January 2018

1 reference

Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy

21 January 2018

1 reference

The chemokine receptors CXCR4 and CXCR3 in cancer

21 January 2018

1 reference

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

21 January 2018

1 reference

Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer

21 January 2018

1 reference

Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.

21 January 2018

1 reference

Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers

21 January 2018

1 reference

Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy

21 January 2018

1 reference

Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression

21 January 2018

1 reference

The pleiotropic functions of the Y-box-binding protein, YB-1.

21 January 2018

1 reference

Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells

21 January 2018

1 reference

Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species

21 January 2018

1 reference

The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma

21 January 2018

1 reference

Upregulation of human DNA binding protein A (dbpA) in gastric cancer cells

21 January 2018

1 reference

Genomic organization of the human Y-box protein (YB-1) gene

21 January 2018

1 reference

YB-1 as a Cell Cycle-regulated Transcription Factor Facilitating Cyclin A and Cyclin B1 Gene Expression

21 January 2018

1 reference

The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance.

21 January 2018

1 reference

Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells

21 January 2018

1 reference

Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition

21 January 2018

1 reference

Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2.

21 January 2018

1 reference

YB-1 binds to the MMP-13 promoter sequence and represses MMP-13 transactivation via the AP-1 site

21 January 2018

1 reference

Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.

21 January 2018

1 reference

Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes

21 January 2018

1 reference

Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor

21 January 2018

1 reference

GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release

21 January 2018

1 reference

21 January 2018

MicroRNAs and cancer.

1 reference

Oncomirs - microRNAs with a role in cancer

21 January 2018

1 reference

Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation

21 January 2018

1 reference

MicroRNAs and their target gene networks in breast cancer

21 January 2018

1 reference

MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer

21 January 2018

1 reference

MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer

21 January 2018

1 reference

mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer

21 January 2018

1 reference

Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer

21 January 2018

1 reference

Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone

21 January 2018

1 reference

Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype.

21 January 2018

1 reference

MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis

21 January 2018

1 reference

Circulating microRNAs as novel minimally invasive biomarkers for breast cancer

21 January 2018

1 reference

hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer

21 January 2018

1 reference

Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1.

21 January 2018

1 reference

Retracted: An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer

21 January 2018

1 reference

MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer

21 January 2018

1 reference

MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1

21 January 2018

1 reference

Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance

21 January 2018

1 reference

Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines

21 January 2018

1 reference

MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.

21 January 2018

1 reference

Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells

21 January 2018

1 reference

Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin

21 January 2018

1 reference

Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.

21 January 2018

1 reference

Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model

21 January 2018

1 reference

MicroRNA let-7: an emerging next-generation cancer therapeutic

21 January 2018

1 reference

Epigenomics and epigenetic therapy of cancer

21 January 2018

1 reference

DNA methylation as a biomarker in breast cancer

21 January 2018

1 reference

Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers

21 January 2018

1 reference

Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome.

21 January 2018

1 reference

Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study

21 January 2018

1 reference

Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer.

21 January 2018

1 reference

Association between frequent CpG island methylation and HER2 amplification in human breast cancers.

21 January 2018

1 reference

Array-based multiplex analysis of DNA methylation in breast cancer tissues

21 January 2018

1 reference

Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia.

21 January 2018

1 reference

Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype

21 January 2018

1 reference

Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer.

21 January 2018

1 reference

Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients

21 January 2018

1 reference

Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen.

21 January 2018

1 reference

Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls

21 January 2018

1 reference

Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker

21 January 2018

1 reference

Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis

21 January 2018

1 reference

Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis

21 January 2018

1 reference

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

21 January 2018

1 reference

DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.

21 January 2018

1 reference

DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients

21 January 2018

1 reference

Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients

21 January 2018

1 reference

DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaborati

21 January 2018

1 reference

The evolution of left-right asymmetry in chordates

21 January 2018

1 reference

Retinoic acid signaling in perioptic mesenchyme represses Wnt signaling via induction of Pitx2 and Dkk2

21 January 2018

1 reference

Pitx2, a beta-catenin-regulated transcription factor, regulates the differentiation of outer root sheath cells cultured in vitro

21 January 2018

1 reference

The Wnt/beta-catenin-->Pitx2 pathway controls the turnover of Pitx2 and other unstable mRNAs

21 January 2018

1 reference

Identification of a Wnt/Dvl/beta-Catenin --> Pitx2 pathway mediating cell-type-specific proliferation during development

21 January 2018

1 reference

Smad3 and Pitx2 cooperate in stimulation of FSHbeta gene transcription

21 January 2018

1 reference

Establishment of left-right asymmetry

21 January 2018

1 reference

Smad5 is essential for left-right asymmetry in mice.

21 January 2018

1 reference

The Pitx2c N-terminal domain is a critical interaction domain required for asymmetric morphogenesis

21 January 2018

1 reference

Proteomic and genomic analysis of PITX2 interacting and regulating networks

21 January 2018

1 reference

BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells

21 January 2018

1 reference

Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells

21 January 2018

1 reference

BMP-4 induction of arrest and differentiation of osteoblast-like cells via p21 CIP1 and p27 KIP1 regulation

21 January 2018

1 reference

Mutations in BMP4 cause eye, brain, and digit developmental anomalies: overlap between the BMP4 and hedgehog signaling pathways

21 January 2018

1 reference

Bone morphogenetic protein 4 contributes to the maintenance of primitive cord blood hematopoietic progenitors in an ex vivo stroma-noncontact co-culture system

21 January 2018

1 reference

Immunohistochemical localization of bone morphogenetic proteins (BMPs) 2, 4, 6, and 7 during induced heterotopic bone formation

21 January 2018

1 reference

Signaling hierarchy regulating human endothelial cell development

21 January 2018

1 reference

A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7.

21 January 2018

1 reference

Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells

21 January 2018

1 reference

BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells.

21 January 2018

1 reference

Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions

21 January 2018

1 reference

Fibroblast growth factors 2, 4, and 8 exert both negative and positive effects on limb, frontonasal, and mandibular chondrogenesis via MEK-ERK activation

21 January 2018

1 reference

Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family

21 January 2018

1 reference

Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer

21 January 2018

1 reference

FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas

21 January 2018

1 reference

Heparin-binding secretory transforming gene (hst) facilitates rat lactotrope cell tumorigenesis and induces prolactin gene transcription

21 January 2018

1 reference

What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics

21 January 2018

1 reference

21 January 2018

1 reference

Prognostic impact of array-based genomic profiles in esophageal squamous cell cancer

21 January 2018

1 reference

Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: comparison with comparative genomic hybridization analysis.

21 January 2018

1 reference

Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma.

21 January 2018

1 reference

Characterization of the FAM110 gene family

21 January 2018

1 reference

Systematic identification of SH3 domain-mediated human protein-protein interactions by peptide array target screening

21 January 2018

1 reference

Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer

21 January 2018

1 reference

Phosphoserine aminotransferase, the second step-catalyzing enzyme for serine biosynthesis

21 January 2018

1 reference

Determining the influence of telomere dysfunction and DNA damage on stem and progenitor cell aging: what markers can we use?

21 January 2018

1 reference

Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells

21 January 2018

1 reference

Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen

21 January 2018

1 reference

Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISA.

21 January 2018

1 reference

The enigmatic protein kinase Cdelta: complex roles in cell proliferation and survival

21 January 2018

1 reference

Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells.

21 January 2018

1 reference

Regulation of protein kinase C delta by estrogen in the MCF-7 human breast cancer cell line

21 January 2018

1 reference

Impact of PKCdelta on estrogen receptor localization and activity in breast cancer cells

21 January 2018

1 reference

Suppression of cell migration by protein kinase Cdelta.

21 January 2018

1 reference

A role for protein kinase C delta in the differential sensitivity of MCF-7 and MDA-MB 231 human breast cancer cells to phorbol ester-induced growth arrest and p21(WAFI/CIP1) induction.

21 January 2018

1 reference

Differential sensitivity of breast cancer cells to tumor necrosis factor-alpha: involvement of protein kinase C.

21 January 2018

1 reference

EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma

21 January 2018

1 reference

Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion

21 January 2018

1 reference

Fibulins 3 and 5 antagonize tumor angiogenesis in vivo

21 January 2018

1 reference

Fez1/Lzts1 a new mitotic regulator implicated in cancer development

21 January 2018

1 reference

Roles of the EZH2 histone methyltransferase in cancer epigenetics

21 January 2018

1 reference

Repression of E-cadherin by the polycomb group protein EZH2 in cancer

21 January 2018

1 reference

Genomic predictors of outcome and treatment response in breast cancer

21 January 2018

1 reference

Commercialized multigene predictors of clinical outcome for breast cancer.

21 January 2018

1 reference

Review of gene-expression profiling and its clinical use in breast cancer

21 January 2018

1 reference

Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays

21 January 2018

1 reference

Trial assessing individualized options for treatment for breast cancer: the TAILORx trial

21 January 2018

1 reference

Multiparametric Prognostic Evaluation of Biological Factors in Primary Breast Cancer

21 January 2018

1 reference

Plasminogen activator inhibitor-1 and prognosis in primary breast cancer

21 January 2018

1 reference

Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer

21 January 2018

1 reference

Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer

21 January 2018

1 reference

p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer

21 January 2018

1 reference

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.

21 January 2018

1 reference

Breast-conserving therapy: proteases as risk factors in relation to survival after local relapse

21 January 2018

1 reference

S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer

21 January 2018

1 reference

The prognostic value of BCAR1 in patients with primary breast cancer.

21 January 2018

1 reference

Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer

21 January 2018

1 reference

Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer

21 January 2018

1 reference

High levels of uPA and PAI-1 predict a good response to anthracyclines

21 January 2018

1 reference

Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer

21 January 2018

1 reference

MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/BMM.10.73

1 reference

23 August 2017

1 reference